2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Shubham Pant, MD, discusses combination immunotherapies and upcoming developments in pancreatic cancer.
Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses combination immunotherapies and upcoming developments in pancreatic cancer.
There is a lot of interest in immunotherapy in the field of oncology; however, this has been more of a challenge in pancreatic cancer, says Pant. However, combination immunotherapies, especially agents that target tumor microenvironments and create a less immune suppressive microenvironment, look promising.
A few different agents are in development to improve the performance status of these patients while they are getting chemotherapy. There are also ongoing trials that measure performance status while they are being treated with chemotherapy and if it improves while receiving active therapy or targeted therapy. These data are being tracked with Fitbits and other devices, concludes Pant.